Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
10 overbought stocks to watch as Wall Street sinks, signaling potential pullbacks
This raises an important question: Are these moves into overbought conditions a signal of potential exhaustion, suggesting ...
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for ...
Mena FN12d
Is The MAGA ETF A Good Way To Profit From Trump's Policies?
Some of the bigger names in the ETF include Yum! Brands (NYSE:YUM), Monster Beverage (NASDAQ:MNST), and Amgen (NASDAQ:AMGN).
Opinion
Arabian Post on MSN12dOpinion
My Recession Risk Call Was Vindicated With Vengeance By Mr. Market!
Matein Khalid I have warned my friends that US recession risk was rising alarmingly in the past month as I saw the price of oil and mone ...
Nasdaq10d
Is General Mills Stock Outperforming the Nasdaq?
Its key strengths lie in its strong brand equity, with iconic names like ... More news from Barchart Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off? Trump Wants to Build ...
The Pharma Letter20d
FDA nod for two Celltrion denosumab biosimilars
South Korea-based Celltrion (Kosdaq: 068270) today announced that the US Food and Drug Administration (FDA) has approved Stoboclo and Osenvelt (CT-P41, denosumab-bmwo), biosimilars referencing Amgen’s ...